Navigation Links
Research shows how 'Mallard' dye fills need for speed
Date:2/14/2013

Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.

Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood. Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.

In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.

The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.

Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.

Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.

"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."

The York researc
'/>"/>

Contact: David Garner
david.garner@york.ac.uk
44-019-043-22153
University of York
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers make racehorses fertile
2. Canadas aquatic ecosystems research gets boost from NSERC
3. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
4. World first for fly research
5. Research improving breast cancer treatment by targeting tumor initiating cells
6. Explosive breakthrough in research on molecular recognition
7. Cities can reduce greenhouse gas emissions by 70 percent, says U of T researcher
8. USC researchers find possible genetic clues to organ development, birth defects
9. Researchers discover Achilles heel for lymphoid leukemia
10. Researchers find Asian needle ants displacing other aggressive invaders
11. NIH grant funds Boston College research into illnesses afflicting people living with HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... release is available in German . ... infants was investigated using the prominent ,Stanford Marshmallow Experiment,: the children ... eat it now or wait and receive a second one if ... several minutes. Interestingly, children that were able to wait for the ...
... March 13, 2013, Shenzhen, China - In a collaborative study ... Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, ... of wild rice Oryza brachyantha . This work provides ... of Oryza genomes. The genus Oryza ...
... up and walked on two legs is considered to be one ... gone to the far ends of the earth and the ... we walk the way we walk. In the latest such ... Africa) have taken a closer look at bipedal kangaroos and wallabies ...
Cached Biology News:Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2It's all in the way we move 2
(Date:4/28/2015)... Showcasing continued leadership in the ... company that provides scientifically advanced, age-defying products, has ... Selling Association (DSA) by the DSA Board of ... period, the DSA confirmed that Nerium’s business practices ... the association: to ensure that direct sales consumers ...
(Date:4/28/2015)... 2015  DanDrit Biotech USA , ... for the treatment of colorectal cancer, is pleased to ... with GISCAD Foundation, a highly recognized Italian group with ... The collaboration relates to VIVA, a Phase III adjuvant ... of disease (NED) Stage IV colorectal cancer (CRC). The ...
(Date:4/28/2015)... 2015  US-Australian drug discovery company, Novogen Limited (ASX: ... a letter from NASDAQ informing it that it had ... Rule). In November 2014, the Company ... to submit a plan to regain compliance with the ... $2,500,000 in stockholders, equity as of June 30, 2014; ...
(Date:4/28/2015)... Calverton, Maryland (PRWEB) April 28, 2015 ... Data Warehouse that bring it to the web ... visualization features and user friendly reporting metrics increase ... save reports for convenient recall and access “on-the-go” ... Warehouse was built using client feedback to assist ...
Breaking Biology Technology:Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 2DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 4Novogen Regains Full Compliance with NASDAQ Listing Rule 2Novogen Regains Full Compliance with NASDAQ Listing Rule 3
... ,, BEIJING, China , May ... or the "Company") a leading developer,manufacturer, and distributor of Shengmingsu brand ... ("PRC"), today announced its,financial results for the quarter ended ... 2010 Highlights, -- Revenue increased 100.5% to $24.9 ...
... RESEARCH TRIANGLE PARK, N.C. , May 12 The International ... Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES).  IES ... early breast cancer and a median follow-up period of 91 months. ... from multiple centers. , , ...
... schedule , , , ... , , ... announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a ... of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and ...
Cached Biology Technology:Yongye International Announces First Quarter 2010 Results 2Yongye International Announces First Quarter 2010 Results 3Yongye International Announces First Quarter 2010 Results 4Yongye International Announces First Quarter 2010 Results 5Yongye International Announces First Quarter 2010 Results 6Yongye International Announces First Quarter 2010 Results 7Yongye International Announces First Quarter 2010 Results 8Yongye International Announces First Quarter 2010 Results 9Yongye International Announces First Quarter 2010 Results 10Yongye International Announces First Quarter 2010 Results 11Yongye International Announces First Quarter 2010 Results 12Yongye International Announces First Quarter 2010 Results 13Yongye International Announces First Quarter 2010 Results 14Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2Resverlogix Completes Dosing for ASSERT Trial 2Resverlogix Completes Dosing for ASSERT Trial 3Resverlogix Completes Dosing for ASSERT Trial 4Resverlogix Completes Dosing for ASSERT Trial 5